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Non-vitamin, non-mineral dietary supplements are 
widely used for health purposes and sometimes as a 
substitute to a healthy diet or conventional medical 
treatments. Nearly 1 in 7 adults takes supplements 
regularly, and approximately 40% have taken one or 
more dietary supplements during their life [1].  
However, despite the widespread and growing use of 
these over-the-counter products, insight into the 
potential beneficial or harmful biological effects of 
these compounds in humans is frequently lacking. 
 
 









































Some individuals, especially heavy supplement users, 
typically consume combinations of dietary supplements 
because they believe that multiple compounds can act 
through complimentary, additive or synergistic 
mechanisms to convey a greater biologic effect than can 
be achieved by any individual supplement [2]. The 
present study was a randomized clinical trial to evaluate 
the effectiveness of supplementation with a combination 
of some of the most self-prescribed dietary supplements 
(i.e. resveratrol, curcumin, green/black/white tea 
extract, quercetin, acetyl-l-carnitine, lipoic acid, 
pomegranate, cinnamon bark, sesamin, and fish oil), in 
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lean and overweight middle-aged men and women 
eating a Western diet. It has been reported that these 
compounds exert powerful protective effects against 
inflammation, oxidative stress/free radical damage, 
insulin resistance, and protein glycation in cell culture 
and laboratory animal studies [3-24]. We evaluated the 
combined effects of these supplements on arterial 
stiffness, endothelial function, markers of inflammation, 







Screening, enrollment, and follow-up information is 
presented in Fig. 1. The study participants were 
generally healthy, as reflected by the following: BMI, 
25.0±2.3 kg/m2; total cholesterol, 187±32 mg/dL; 
triglycerides, 79±53 mg/dL; fasting glucose, 82±9 
mg/dL; and systolic and diastolic blood pressures of 
109±12 and 68±8 mmHg, respectively. The proportions 
of men and women did not differ between groups 
(p=0.65). The average age of participants was slightly 
lower in the SUP group (means±SD: 44±6 vs. 47±5 yr, 
p=0.05). BMI did not differ (p=0.65) between the SUP 
(25.2±2.0 kg/m2) and  control  (24.9±2.5 kg/m2)  groups. 



























participants in the SUP group took all of the prescribed 
doses of the supplements. All participants in both 
groups complied with the vitamin/mineral 
supplementation regimen. 
 
There were no differences between groups in PWV, AI, 
blood pressure, and endothelium-dependent and 
endothelium-independent brachial artery vasodilation 
(Table 1). No changes in body weight or % total body 
fat occurred in either study group (Table 2). Plasma 
lipid concentrations and indices of glucoregulation did 
not change in either group (Table 2). No differences 
between groups were observed for markers of 
inflammation, oxidative stress and glycation, and blood 
counts (Table 2).  Serum insulin and IGF-1 
concentrations did not change in either group (Table 2). 
Since completing the randomized trial, all but one of the 
participants in the SUP group continued for another 6 
months on the supplementation regimen. Even with this 
longer, 12 month period of supplementation, no changes 
in any outcome were observed (data not shown). 
 
No serious adverse events occurred. Serum markers of 
liver and kidney function were unaffected by 
supplementation. Other adverse events were limited to 
mild gastrointestinal discomfort associated with taking 









































































Our findings indicate that daily use of multiple dietary 
supplements has no effect on arterial stiffness (i.e. pulse 
wave velocity and augmentation index), endothelial 
function (i.e. brachial artery flow-dependent 
vasodilatation) or blood pressure in nonobese men and 
women. Furthermore, supplementation with these 
compounds did not affect key metabolic variables 
implicated in the biology of aging, and in the 













































markers of inflammation, oxidative stress and glycation, 
plasma lipids, growth factors, or body composition. 
 
Reports from studies conducted mainly on cells in 
culture or in experimental animals suggest that these 
compounds promote metabolic health and may have 
anti-aging effects [4-24]. In particular, resveratrol, 
quercetin, curcumin, acetyl-L-carnitine, lipoic acid, fish 
oil, sesamin, pomegranate, cinnamon bark, and green 
tea extracts have all been reported to have powerful 
anti-oxidant and/or anti-inflammatory properties [4-24].  
 
Table 1. Effect of 6 months of nutritional supplements or control on indices of arterial stiffness, vasomotor 











Pulse wave velocity, m/s 
   Baseline 
   6 months 
   Change 
 
5.4 ± 0.3 
4.8 ± 0.3 
-0.5 ± 0.4 
 
5.2 ± 0.2 
5.3 ± 0.2 









Augmentation index, % 
   Baseline 
   6 months 
   Change 
 
11.7 ± 2.6 
12.5 ± 2.8 
0.8 ± 1.1 
 
12.3 ± 2.8 
13.0 ± 2.3 









Flow-mediated dilation, % 
   Baseline 
   6 months 
   Change 
 
5.0 ± 0.5 
4.5 ± 0.4 
-0.5 ± 0.5 
 
4.1 ± 0.4 
4.4 ± 0.3 









GTN-mediated dilation, % 
   Baseline 
   6 months 
   Change 
 
16.1 ± 1.3 
14.2 ± 1.6 
-1.9 ± 1.1 
 
14.6 ± 1.2 
13.3 ± 0.9 









Systolic BP, mmHg 
   Baseline 
   6 months 
   Change 
 
108 ± 2 
108 ± 2 
0 ± 1 
 
109 ± 2 
107 ± 3 









Diastolic BP, mmHg 
   Baseline 
   6 months 
   Change 
 
69 ± 1 
69 ± 1 
0 ± 1 
 
66 ± 2 
64 ± 2 









Values are arithmetic means ± SE except for mean differences between groups, which have been adjusted for 
baseline values. Between-group P values reflect the between-group comparison change-scores from 
ANCOVAs that included baseline values as the covariate. *Significant (p≤0.05) within-group change. GTN, 
nitroglycerine; BP, blood pressure. Several subjects in the supplement group (n=15) and control group (n=14) 
did not undergo testing for GTN-mediated dilation because systolic blood pressure was below 100 mmHg, 
which is a contraindication to GTN administration. 
  

















































































































Table 2. Risk factors for cardiovascular disease and diabetes, and circulating markers of oxidative stress, 
chronic inflammation, in response to 6 months of nutritional supplementation or control. 










Body Mass and Composition 
Body mass, kg 
   Baseline 
   6 months 
   Change 
 
73.8 ± 2.3 
74.2 ± 2.5 
0.3 ± 0.4 
 
72.8 ± 1.8 
73.1 ± 1.7 









Body fat, % 
   Baseline 
   6 months 
   Change 
 
30.1 ± 1.1 
29.9 ± 1.0 
-0.2 ± 0.3 
 
30.2 ± 1.7 
30.3 ± 1.8 











   Baseline 
   6 months 
   Change 
 
79 ± 12 
75 ± 6 
-4 ± 11 
 
78 ± 8 
87 ± 8 









Total cholesterol, mg/dL 
   Baseline 
   6 months 
   Change 
 
186 ± 6 
186 ± 6 
-1 ± 4 
 
189 ± 6 
192 ± 5 










   Baseline 
   6 months 
   Change 
 
110 ± 6 
111 ± 5 
1 ± 3 
 
114 ± 6 
115 ± 5 










   Baseline 
   6 months 
   Change 
 
61 ± 3 
59 ± 3 
-2 ± 2 
 
61 ± 3 
60 ± 3 










Fasting glucose, mg/dL 
   Baseline 
   6 months 
   Change 
 
80 ± 2 
83 ± 2 
3 ± 2 
 
84 ± 2 
85 ± 2 









Fasting insulin, µU/mL 
   Baseline 
   6 months 
   Change 
 
3.3 ± 0.3 
3.6 ± 0.4 
0.3 ± 0.3 
 
2.8 ± 0.3 
2.9 ± 0.3 










   Baseline 
   6 months 
   Change 
 
0.64 ± 0.06 
0.74 ± 0.09 
0.10 ± 0.06 
 
0.60 ± 0.06 
0.63 ± 0.06 



























































































































Table 2 (continued). Risk factors for cardiovascular disease and diabetes, and circulating markers of oxidative 
stress, chronic inflammation, in response to 6 months of nutritional supplementation or control. 











Inflammatory Cytokines and Oxidative Stress Markers
CRP, mg/L 
   Baseline 
   6 months 
   Change 
 
1.69 ± 0.48 
1.51 ± 0.20 
-0.17 ± 0.49 
 
1.21 ± 0.52 
1.44 ± 0.56 










   Baseline 
   6 months 
   Change 
 
1.92 ± 0.09 
1.94 ± 0.09 
0.02 ± 0.05 
 
2.10 ± 0.18 
2.13 ± 0.19 










   Baseline 
   6 months 
   Change 
 
1.26 ± 0.26 
1.35 ± 0.23 
0.08 ± 0.08 
 
1.39 ± 0.31 
1.68 ± 0.32 









Protein carbonyl, nmol/mg 
   Baseline 
   6 months 
   Change 
 
 
0.83 ± 0.03 
0.76 ± 0.03 
-0.07 ± 0.04 
 
 
0.79 ± 0.03 
0.82 ± 0.03 












   Baseline 
   6 months 
   Change 
 
307 ± 14 
287 ± 12 
-20 ± 13 
 
272 ± 13 
270 ± 12 









White Cell Counts and Growth Factors
WBC, k/cumm 
   Baseline 
   6 months 
   Change 
 
5.1 ± 0.2 
5.0 ± 0.2 
-0.1 ± 0.2 
 
4.8 ± 0.2 
5.1 ± 0.3 










   Baseline 
   6 months 
   Change 
 
1.50 ± 0.05 
1.42 ± 0.06 
-0.08 ± 0.04* 
 
1.42 ± 0.09 
1.44 ± 0.10 










   Baseline 
   6 months 
   Change 
 
145 ± 6 
151 ± 7 
6 ± 5 
 
148 ± 7 
144 ± 6 









Values are arithmetic means ± SE except for mean differences between groups which have been adjusted for 
baseline values.  Between-group P values reflect the between-group comparison change-scores from 
ANCOVAs that included baseline values as the covariate. *Significant (p≤0.05) within-group change. 
Triglyceride data were also adjusted for a significant effect of age on the baseline to follow up changes. 
Within-group P values are from paired t-tests.  LDL, low density lipoprotein; HDL, high density lipoprotein; 
HOMA-IR, homeostasis model assessment of insulin resistance; CRP, C-reactive protein, TNFα, tumor 
necrosis factor α; IL-6, interleukin-6; AGEs, advanced glycation end products; WBC, white blood cells; IGF-1, 
insulin-like growth factor-1. To convert units to SI units, multiply the conventional units by the following 
conversion factors: triglycerides x 0.0113 = mmol/L; total, LDL-, and HDL-cholesterol x 0.0259 = mmol/L; 
glucose x 0.0555 = mmol/L; insulin x 6.945 = pmol/L.   
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However, in our study we did not see any reduction in 
markers of inflammation or oxidative stress. Oxidative 
stress and inflammation are major players in the 
pathogenesis of arterial aging and endothelial 
dysfunction, which is a precursor of atherosclerosis [25-
29]. Nevertheless, pulse wave velocity, augmentation 
index and endothelium-dependent vasorelaxation did 
not improve in the supplement group. Furthermore, 
supplementation with these compounds did not alter 
other well-accepted cardiometabolic risk factors, 
including blood pressure, insulin resistance, and serum 
cholesterol, triglyceride and advanced glycation end-
products concentrations. Endothelial function can be 
improved with just a single infusion of the anti-oxidant, 
vitamin C [30]. Because all the supplements that we 
used have been reported to have powerful anti-
inflammatory and anti-oxidant effects, it is interesting 
that no biological change in endothelial function was 
observed. In contrast, it has been shown that 6-mo or 1-
yr supplementation with DHEA-s results in significant 
improvements of glucose tolerance, arterial stiffness 
and inflammation [31]. 
 
One possible explanation for the lack of beneficial 
metabolic effects of these over-the counter dietary 
supplements could be the low phytochemical 
bioavailability or inadequate supplement potency of the 
phytochemicals contained in some of these compounds 
which are available without prescription [32]. 
Nonetheless, the fact remains that millions of 
individuals in USA and Europe are consuming these 
supplements, sometimes instead of a healthy diet and 
conventional medical treatment, which might contain 
hazard trace amounts of pesticides and heavy metals, 
including lead, arsenic, mercury, and cadmium [1,33]. 
A placebo was not provided to control group 
participants in the present study, which might be viewed 
as a limitation. However, while a “placebo effect” might 
have been an explanation for significant changes in the 
supplement group, we did not observe changes. 
Therefore, in this context, the lack of a placebo is not a 
limitation. Moreover, although the sample size was 
relatively small, there was no suggestion of clinically 
significant differences from the between-group 
estimates, despite multiple comparisons. Finally, it is 
conceivable that some supplements might have had 
beneficial effects that where counteracted by negative 
effects of others. However, this seems unlikely and 
people rarely take isolated supplements, and many of 
these compounds are contained in foods and beverages 
that are consumed regularly by millions of people. 
Moreover, heavy supplement users believe that these 
compounds work better in combination, because as with 
food and beverages, they provide a mix of phyto-
chemicals that interact and potentiate their effect (e.g. 
resveratrol in wine, cathechins in green and black tea,  
pomegranate in fruits, curcumin in spices, etc.). 
Findings from the present study suggest that a 
combination of several popular nutritional supplements, 
which are commonly taken with the intention of 
promoting healthy longevity and preventing chronic 
disease, have no effects on arterial stiffness, endothelial 
function, inflammation, oxidative stress, and other 
chronic disease risk factors in non-obese men and 
women. Additional randomized controlled studies are 
still needed to assess the potential benefits of these and 





Participants. Non-obese (BMI 21.0-29.9 kg/m2) men 
and women, aged 38-65y were recruited from the Saint 
Louis area. Participants were free of chronic disease 
based on a medical history, physical examination, blood 
and urine chemistries, and electrocardiogram. Exclusion 
criteria included chronic use of medications or dietary 
supplements, tobacco use, alcohol abuse, and habitual 
vigorous exercise. Participants consented to participate 
in the study, which was approved by the Washington 
University Institutional Review Board. 
 
Study Design. The study was a 6-month single-blind 
controlled trial in which participants were randomized 
(1:1 ratio with stratification for sex) to a nutritional 
supplement (SUP) group or control (CON) group. At 
the end of the RCT, the participants who had been 
randomized to SUP continued taking the supplements 
for another 6-mo, while those who had been in the CON 
group crossed over to the supplementation regimen for 
6-mo. Technicians who performed outcomes 
assessments were blinded to study group assignments. 
Participants fasted overnight (12-hr) and refrained from 
exercise for 24-hr before testing. For follow-up tests, 
participants in the SUP group were instructed to take 
their nutritional supplements upon waking in the 
morning prior to testing. The primary outcome, carotid-
femoral pulse wave velocity (PWV), was measured by 
using Doppler flow measures. Another index of arterial 
stiffness, carotid artery augmentation index (AI) was 
measured using applanation tonometry. Endothelium-
dependent and endothelium-independent brachial artery 
vasodilation were evaluated by using ultrasound 
imaging to measure flow-mediated dilation and glyceryl 
trinitrate- (GTN)-mediated dilation, respectively. 
 
Intervention. Participants in the SUP group took the 
following dietary supplements: resveratrol (100 
mg/day), quercetin (650 mg/day), acetyl-l-carnitine 
HCL (500/mg/day), alpha-lipoic acid (600 mg/day), 
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curcumin complex (900 mg/day; standardized to 95% 
total curcuminoids, plus piperine 5 mg), pomegranate 
extract (250 mg/day; standardized to 70% ellagic acid), 
fish oil (1 g/day, containing 300 mg of eicosapentaenoic 
acid and 200 mg docosahexaenoic acid), cinnamon bark 
(1.7 g/day), green/white/black tea complex (800 mg/day 
each of green, black, and white tea extract) and sesamin 
(1 g/day; standardized to 500 mg sesamin lignans). 
Sesamin was formulated by Scivation, Inc. (Burlington, 
NC, USA) and all others by Swanson Health Products 
(Fargo, ND, USA). Both groups received a daily 
multivitamin/mineral supplement (Daily Multi-Vitamin 
& Mineral, Swanson, Fargo, ND, USA) and were 
advised to maintain their usual diet and physical 
activity. Participants met with a member of the research 
team each month to receive supplements and to answer 
questions about compliance with the supplementation 
regimen, changes in diet, physical activity, medical 
conditions, and medication use, and adverse events. 
 
Body weight and composition. Weight and height were 
measured with a calibrated balance beam scale and 
wall-mounted stadiometer, respectively, with the 
participant wearing only a hospital gown and 
underwear. BMI was calculated (kg/m2). Body 
composition was evaluated using dual energy X-ray 
absorptiometry (Delphi W, software version 11.2, 
Hologic Corp., Waltham, MA). Bilateral brachial artery 
blood pressure was measured with a calibrated monitor 
(Dinamap 1846 SX, Critkon, Inc, Tampa, FL) according 
to JNC 7 guidelines. 
 
Circulating biomarkers of disease risk and aging. Blood 
samples were collected from a forearm vein into 
separate tubes containing sodium heparin, EDTA, and 
no additives. Plasma and serum were isolated by 
centrifugation (3500 g, 15 min, 4º C) and stored at -80º 
C for later batch analyses. Samples were analyzed for 
plasma concentrations of glucose (glucose oxidase 
method, 2300 Stat Plus, YSI Inc., Yellow Springs, OH) 
and insulin (chemiluminescence assay, Immulite 1000, 
Siemens USA, Malvern, PA). The homeostasis model 
assessment of insulin resistance (HOMA-IR) was 
calculated from fasting glucose and insulin. ELISA 
assay kits were used to measure serum concentrations of 
inflammatory cytokines (tumor necrosis factor α 
(TNFα), interleukin-6 (IL-6), C-reactive protein (CRP), 
Quantikine, R&D Systems, Minneapolis, MN), 
oxidative stress markers (protein carbonyls (Cell 
Biolabs, San Diego, CA) and advanced glycation end-
product (AGE) N-1-carboxymethyl lysine (MBL 
International, Woburn, MA)), and insulin-like growth 
factor-1 (IGF-1, Diagnostic Systems Laboratories, 
Webster, TX). Plasma lipids and blood counts were 
measured by a CLIA-certified clinical laboratory at the 
medical center. 
 
Indices of arterial stiffness. Carotid artery augmentation 
index (AI) was measured by using applanation 
tonometry according to published guidelines [34]. 
Twenty digital pulse waves were recorded with a 
tonometer (Millar Instruments, Inc., Model #TCB-500, 
Houston, TX) and analyzed with Windaq software 
(version 2.31, DATAQ Instruments, Inc., Akron, OH). 
The the maximum and minimum voltage on each wave 
form was identified and used to calculate pulse pressure 
(PP). The second derivative of the pulse wave was 
generated and used to identify the “shoulder” on the 
upstroke of the raw wave form. Augmentation pressure 
(AP) was calculated as the difference between the peak 
voltage and the voltage at the shoulder. Augmentation 
index was calculated as AI = 100 × AP/PP for each of 
the 20 waveforms; the resulting values were averaged. 
Because AI is dependent on heart rate, AI values were 
adjusted to a standardized heart rate of 75 beats/min 
based on the inverse relationship of 4.8 AI units per 10 
beats/min HR [35]. The technician visually inspected all 
waveforms to ensure that the landmarks had been 
properly identified and to omit waveforms that were of 
suboptimal quality due to artifacts or irregular 
heartbeats. When analyses were questionable (e.g. large 
variation in AI values among waveforms), the 
waveforms were re-analyzed by another technician. If 
discrepancies between the analyses occurred, the 
technicians reviewed the analyses together and if the 
differences could not be remediated, the data were 
excluded. 
 
Pulse wave velocity (PWV) was determined according 
to standard procedures1 by using transcutaneous 
Doppler flow measurements (Model 806-CB, Parks 
Medical Electronics, Inc., Aloha, OR) at the right 
common carotid artery and the right femoral artery. 
Twenty Doppler wave forms were simultaneously 
recorded (Windaq software, version 2.31, DATAQ 
Instruments, Inc., Akron, OH) at the two sites. Pulse 
transit time was determined as the difference in pulse 
arrival times (based on the “foot” of the pulse wave, as 
determined from the second derivative of the pulse 
wave) for the carotid and femoral sites. Pulse transit 
distances between the aorta and the carotid site and the 
aorta and the femoral site were measured over the skin 
using the second intercostal space as a landmark for the 
aorta, with the difference between these distances being 
considered the pulse propagation distance [36]. PWV 
was calculated for each of the 20 pulses as the quotient 
of the propagation distance (in meters) and transit time 
(in seconds) and the 20 values were averaged. Quality 
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control procedures were identical to those described 
above for the AI method. 
 
Vascular function. Brachial artery flow mediated 
dilation (FMD) was used to measure endothelium-
dependent vasodilation and glyceryl trinitrate- (GTN)-
mediated dilation was used to measure endothelium-
independent vasodilation. The participant’s right arm 
was immobilized with the shoulder abducted at 70-90º 
and elbow fully extended. Ultrasound images were 
acquired using an ultrasound system (Agilent SONOS 
5500, Andover, Massachusetts) equipped with an 11-3L 
linear array transducer. The probe was secured using a 
stereotactic clamp (Noga Engineering, Ltd.) to maintain 
constant positioning over the artery throughout the 
procedure. Ultrasound images were fed to a computer 
for real time quantification of arterial diastolic diameter 
(30 ± 2 measures/sec) using Vascular Imaging Analysis 
software (VIA, version 9.60) [37]. Baseline diameter 
was recorded for 2 minutes before a pneumatic cuff 
(Hokanson E20 Rapid Cuff Inflator and AG101 Cuff 
Inflator Air Source, PMS Instruments, Ltd., 
Maidenhead, UK) was inflated to 200 mmHg on the 
right forearm to occlude blood flow. After 5 minutes of 
occlusion, the pressure in the cuff was rapidly released 
and arterial diameter was recorded continuously for 5 
minutes. FMD was calculated as the percent increase in 
diameter from baseline to peak diameter, where baseline 
diameter was the average diastolic diameter over the 2-
minute baseline and peak diameter was recorded as the 
10-second average of the highest diastolic diameter 
after cuff deflation. After the FMD assessment, and 
after the diameter of the artery returned to baseline, a 
second 2-minute baseline data collection was 
performed, followed by administration of 0.4 mg 
sublingual GTN spray. Brachial artery diameter was 
evaluated again 5 minutes after GTN administration.  
GTN-mediated dilation was calculated as the percentage 
increase in arterial diameter from baseline to 5 minutes 
after GTN administration. 
 
Statistical Power and Analyses. Sample size estimates 
were calculated for PWV, as a measure of arterial 
stiffness and for interleukin-6 (IL-6) and C-reactive 
protein (CRP) as inflammatory markers. Calculations 
were based on data collected in our laboratory during 
previous studies. These studies included a randomized 
controlled trial on the effects of 50 mg/d oral DHEA 
supplementation on markers of aging in older adults 
[31] and cross-sectional [38] and longitudinal studies 
[39] on the effects of calorie restriction on markers of 
aging in middle-aged adults. For all sample size 
calculations, the alpha error rate was set at 0.05, tests 
were designated as two-tailed, desired power was set to 
0.80, and the ratio of participants to be randomized to 
the intervention and no-treatment control groups was 
1:1. Results indicate that 21 subjects per group would 
be sufficient for detecting a 3.1 m/sec improvement in 
pulse wave velocity, 27 subjects per groups would be 
sufficient for detecting a 0.86 ng/mL reduction in IL-6, 
and 12 subjects per groups would be sufficient for 
detecting a 1.60 mg/L reduction in CRP. Therefore, our 
proposed sample size of 56 participants (28 per group) 
was sufficient to detect biologically relevant changes in 
arterial stiffness and inflammation. 
 
Power analyses were performed for PWV, IL-6, and 
CRP to determine sample size. Respective results 
indicated that sample sizes of 21, 27, and 12 subjects 
per group would be adequate for detecting significant 
effects. Therefore, 28 subjects per group was chosen. 
Baseline characteristics were compared with 
independent t-tests and chi-square tests. Outcomes were 
analyzed with analysis of covariance, in which baseline 
values were included as a covariate. Paired t-tests were 
used for within-group paired comparisons. Significance 
was accepted at p≤0.05 and tests were two-tailed. 
Analyses were conducted with SAS for Windows XP 
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